Drs. Kevin Pauza, Gregory Lutz launch study into non-invasive degenerated disc treatment: 5 highlights

Written by Mackenzie Garrity | March 12, 2018 | Print  |

Gregory Lutz, MD, and Kevin Pauza, MD, launched a new study to examine the clinical effectiveness of Discseel, a treatment to restore and regrow damaged discs in the spine.

Here are five highlights:

 

1. The surgeons are conducting the study to demonstrate the procedures success. Discseel is the first treatment designed to replace spinal fusion procedures.

 

2. Discseel is also the first of its kind to use an FDA-approved biologic to seal and regrow degenerated discs. A study found only 3 percent of bulging discs heal on their own.

 

3. Dr. Lutz and Dr. Pauza will study whether fibrin, used alone or with the addition of a patient's own cells, will repair damaged discs, reduce lower back pain and improve function.

 

4. The injected fibrin is designed to act as a sealant, creating a physical barrier between the disc's center gel, which is the source of inflammation.

 

5. Early on and at 10-year follow-ups, Discseel has shown successful results. In 2016, Dr. Lutz published data from a study that established the safety and efficacy of intradiscal PRP therapy. Dr. Pauza also conducted research on a natural disc sealing process.

 

This new study combines the successes of their study findings.

 

More articles on biologics:
4 things to know about mensenchymal stromal cells in spine
7 things to know about Dr. Marshall R. Urist, bone morphogenetic protein pioneer
Study: use of biologics before or during pregnancy not associated with preterm delivery — 3 insights

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies here.